Education
About Us
Working with TipRanks
Follow Us
Stereotaxis (STXS)
:STXS
STXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.66 - $3.29
Previous CloseN/A
Volume282.58K
Average Volume (3M)657.96K
Market Cap
$161.64M
Enterprise Value$175.61M
Total Cash (Recent Filing)$9.04M
Total Debt (Recent Filing)$5.59M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
May 13, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding85,979,660
10 Day Avg. Volume807,440
30 Day Avg. Volume657,960
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.13
Price to Cash Flow (P/CF)32.60
P/FCF Ratio29.80
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.03
Enterprise Value/Ebitda-8.16
Forecast
1Y Price Target
$4.67Price Target Upside148.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial HealthSTXS likely ended 2024 with approximately $12M in cash and no debt, which could allow for the commercialization of its next-generation product ecosystem and reach profitability without additional financing.
Innovative PartnershipsSTXS's acceptance into the NVIDIA Connect program marks a pivotal milestone in its long-term innovation strategy, enabling future advanced AI integration to enhance robotic precision, automation, and decision support.
Market ExpansionThe approval of the Magbot catheter in China is another key win, ahead of what should be a big year for STXS in 2025.
Bears Say
Financial PerformanceThe 4Q operating loss was $7.6M, while the net loss was $7.5M.
---
Ownership Overview
23.01% Insiders
7.08% Mutual Funds
32.85% Other Institutional Investors
30.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.66 and its highest was $3.29 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $161.64M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is May 13, 2025 which is in 45 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on Mar 03, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.065 by -$0.025.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.07.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 85,979,660 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.065. Following the earnings report the stock price went down -5.825%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
---
Stereotaxis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.67 (148.40% Upside)
$4.67 (148.40% Upside)
Blogger Sentiment
Bullish
STXS Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $113.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.09%
12-Months-Change
Fundamentals
Return on Equity
-144.19%
Trailing 12-Months
Asset Growth
11.49%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. (STXS) is a leading medical technology company specializing in the development and commercialization of advanced robotic systems for the treatment of cardiac arrhythmias. The company operates within the healthcare and medical devices sector, focusing on providing innovative solutions that enhance the precision and safety of minimally invasive surgery. Its core products include the Niobe Magnetic Navigation System and the Genesis RMN System, which facilitate remote-controlled, magnetic-guided catheter navigation, enabling electrophysiologists to perform complex cardiac procedures with improved accuracy and reduced risk.
---
STXS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Stereotaxis demonstrated strong revenue growth and made significant progress with FDA submissions and strategic acquisitions, which are expected to drive future growth. However, system revenue showed a slight decline, and recurring revenue faced challenges due to external dependencies. The company also reported a higher operating loss and commercial uncertainties in China. Overall, the call presents a balanced picture with potential for future growth tempered by current financial and market challenges.Read More>---
STXS Stock 12 Month Forecast
Average Price Target
$4.67
▲(148.40% Upside)
Technical Analysis
Best Analysts Covering STXS
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
-3.00%
reiterated a buy rating 11 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -3.00% per trade.
---